berdazimer · Zelsuvmi
Small molecule
Also known as SB206
Evidence outlook
Approved: Molluscum Contagiosum
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04535531 NCT04535531 · Molluscum Contagiosum This was a randomized, double-blind, vehicle-controlled trial that enrolled 891 participants against a planned 850, with a power calculation reported. Its primary endpoint, complete clearance of all lesions at week 12, was met: 32.4% with berdazimer versus 19.7% with vehicle (odds ratio 2.0, P < .001). Registry: NCT04535531 | 3 | Complete Clearance of All Treatable MC at Week 12 (12 Weeks) 2021-04-28 | Complete clearance of all molluscum lesions at week 12, berdazimer gel 10.3% vs vehicle: 32.4% (144/444) vs 19.7% (88/447); absolute difference 12.7%, OR 2.0 (95% CI 1.5 to 2.8), p<0.001 (Sugarman 2022, JAMA Dermatology; B-SIMPLE4). | Reliable signal | link ↗ |
View 2 more trials
NCT03927703 NCT03927703 · Molluscum Contagiosum This was a randomized, double-blind, vehicle-controlled trial of 355 participants, above its planned 340, with a power calculation in the protocol. Its primary endpoint, complete clearance of all lesions at week 12, favored berdazimer (30.0% vs 20.3%), and the FDA label states efficacy was demonstrated in this trial, although the reported 95% confidence interval for the difference only just reaches zero (-0.04% to 18.4%). Registry: NCT03927703 | 3 | Complete Clearance of All Treatable MC at Week 12 (12 Weeks) 2019-11-11 | Complete clearance of all molluscum lesions at week 12, berdazimer (SB206 12%) vs vehicle: 30.0% (n=237) vs 20.3% (n=118); treatment difference 9.2% (95% CI -0.04% to 18.4%). The FDA label states efficacy was demonstrated in this trial (Trial 2, B-SIMPLE2). | Reliable signal | link ↗ |
NCT03927716 NCT03927716 · Molluscum Contagiosum This was a randomized, double-blind, vehicle-controlled trial of 352 participants with complete lesion clearance at week 12 as its primary endpoint. Berdazimer did not separate from vehicle (26% vs 22%, 95% confidence interval for the difference -5% to 14%), and the FDA label counts efficacy as demonstrated only in the other two trials. Registry: NCT03927716 | 3 | Complete Clearance of All Treatable MC at Week 12 (12 Weeks) 2019-10-28 | Complete clearance of all molluscum lesions at week 12, berdazimer (SB206 12%) vs vehicle: 26% vs 22%, 95% CI for the difference -5% to 14% (FDA label, Trial 3). CT.gov counts: 61/236 vs 25/116. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.